Thelansis

Non–Shiga toxin-associated HUS (non–Stx-HUS) Market Outlook Thelansis’s “Non–Shiga toxin-associated HUS (non–Stx-HUS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non–Shiga toxin-associated HUS (non–Stx-HUS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which e...

Non–Shiga toxin-associated HUS (non–Stx-HUS) Market Outlook Thelansis’s “Non–Shiga toxin-associated HUS (non–Stx-HUS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non–Shiga toxin-associated HUS (non–Stx-HUS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Non–Shiga toxin-associated HUS (non–Stx-HUS) Overview Non–Shiga toxin-associated HUS (non–Stx-HUS) comprises a heterogeneous group of patients in whom an infection by Stx-producing bacteria could be excluded as the cause of the disease. It can be sporadic or familial, with more than one family member affected by the disease and exposure to Stx-E. Coli excluded. Collectivel...

 Non–Shiga toxin-associated HUS (non–Stx-HUS) comprises a heterogeneous group of patients in whom an infection by Stx-producing bacteria could be excluded as the cause of the disease. It can be sporadic or familial, with more than one family member affected by the disease and exposure to Stx-E. Coli excluded. Collectively, non–Stx-HUS forms have a poor outcome. Up to 50% of cases progress to ESRD or have irreversible brain damage, and 25% may die during the acute phase of the disease. After exposure to Stx-E. Coli, 38 to 61% of individuals, develop hemorrhagic colitis and 3 to 9% (in sporadic infections) to 20% progress to overt HUS. The average interval between E. coli exposure and illness is three days. Disease typically begins with abdominal cramps and nonbloody diarrhea; diarrhea may become hemorrhagic in 70% of cases, usually within 1 or 2 d. Vomiting occurs in 30 to 60% of cases, and fever occurs in 30%. Leukocyte count is generally elevated, and a barium enema may demonstrat...